KalVista Pharmaceuticals (NASDAQ:KALV) Upgraded by Wall Street Zen to “Hold” Rating

KalVista Pharmaceuticals (NASDAQ:KALV) was upgraded by Wall Street Zen from a “sell” rating to a “hold” rating in a research note issued on Saturday.

A number of other research analysts have also recently commented on KALV. Weiss Ratings restated a “sell (d-)” rating on shares of KalVista Pharmaceuticals in a research note on Wednesday, October 8th. Cowen reissued a “buy” rating on shares of KalVista Pharmaceuticals in a research note on Wednesday. Citizens Jmp dropped their target price on KalVista Pharmaceuticals from $29.00 to $28.00 and set a “market outperform” rating for the company in a research report on Tuesday, November 11th. Needham & Company LLC reiterated a “buy” rating and set a $28.00 price target on shares of KalVista Pharmaceuticals in a research note on Thursday. Finally, Citigroup reissued a “market outperform” rating on shares of KalVista Pharmaceuticals in a research note on Tuesday, November 11th. Eleven investment analysts have rated the stock with a Buy rating and one has given a Sell rating to the company’s stock. According to MarketBeat, KalVista Pharmaceuticals has a consensus rating of “Moderate Buy” and an average target price of $26.63.

KalVista Pharmaceuticals Trading Up 0.2%

Shares of KALV stock opened at $16.43 on Friday. KalVista Pharmaceuticals has a 1-year low of $7.30 and a 1-year high of $17.28. The firm has a market cap of $830.54 million, a PE ratio of -4.16 and a beta of -0.14. The company has a 50-day moving average of $12.29 and a two-hundred day moving average of $13.00. The company has a debt-to-equity ratio of 8.18, a current ratio of 7.22 and a quick ratio of 7.21.

KalVista Pharmaceuticals (NASDAQ:KALV) last issued its quarterly earnings data on Monday, November 10th. The specialty pharmaceutical company reported ($0.92) EPS for the quarter, topping the consensus estimate of ($0.96) by $0.04. The company had revenue of $13.69 million during the quarter, compared to analyst estimates of $6.03 million. On average, analysts predict that KalVista Pharmaceuticals will post -3.56 EPS for the current year.

Insider Buying and Selling at KalVista Pharmaceuticals

In other news, insider Paul K. Audhya sold 5,296 shares of KalVista Pharmaceuticals stock in a transaction dated Monday, November 24th. The stock was sold at an average price of $13.45, for a total value of $71,231.20. Following the completion of the transaction, the insider owned 131,831 shares in the company, valued at approximately $1,773,126.95. This trade represents a 3.86% decrease in their position. The sale was disclosed in a filing with the SEC, which can be accessed through the SEC website. Also, CFO Brian Piekos sold 4,471 shares of the company’s stock in a transaction that occurred on Monday, November 24th. The stock was sold at an average price of $13.45, for a total transaction of $60,134.95. Following the sale, the chief financial officer owned 10,529 shares in the company, valued at $141,615.05. The trade was a 29.81% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Insiders have sold 31,329 shares of company stock valued at $432,485 in the last quarter. Corporate insiders own 4.30% of the company’s stock.

Institutional Investors Weigh In On KalVista Pharmaceuticals

Several institutional investors have recently modified their holdings of KALV. Sherbrooke Park Advisers LLC purchased a new position in KalVista Pharmaceuticals in the third quarter valued at $191,000. Qube Research & Technologies Ltd boosted its position in shares of KalVista Pharmaceuticals by 234.6% during the 3rd quarter. Qube Research & Technologies Ltd now owns 325,435 shares of the specialty pharmaceutical company’s stock worth $3,964,000 after acquiring an additional 228,187 shares in the last quarter. Parkman Healthcare Partners LLC increased its holdings in shares of KalVista Pharmaceuticals by 155.5% in the 3rd quarter. Parkman Healthcare Partners LLC now owns 1,735,003 shares of the specialty pharmaceutical company’s stock valued at $21,132,000 after acquiring an additional 1,055,940 shares during the last quarter. Brevan Howard Capital Management LP raised its position in shares of KalVista Pharmaceuticals by 319.1% during the 3rd quarter. Brevan Howard Capital Management LP now owns 55,878 shares of the specialty pharmaceutical company’s stock worth $681,000 after acquiring an additional 42,545 shares in the last quarter. Finally, Creative Planning lifted its stake in KalVista Pharmaceuticals by 13.9% during the third quarter. Creative Planning now owns 38,032 shares of the specialty pharmaceutical company’s stock worth $463,000 after purchasing an additional 4,652 shares during the last quarter.

KalVista Pharmaceuticals Company Profile

KalVista Pharmaceuticals, Inc, a clinical stage pharmaceutical company, engages in the discovery, development, and commercialization of drug therapies inhibitors for diseases with unmet needs. The company’s product candidate is Sebetralstat, a small molecule plasma kallikrein inhibitor targeting the disease of hereditary angioedema (HAE).